Innovating Science and Delivery Technologies

George Hornig was appointed Chairman of the Board in May 2024. He is the former Chairman of Xometry, joining its board in 2013, and previously served as Co-Chairman and Audit Chair of Healthwell Acquisition Corp. He is Managing Partner and Co-Founder of The Seed Lab and a former director of Syntax Advisors. Earlier roles include senior leadership at PineBridge Investments, Credit Suisse Asset Management, and Deutsche Bank Americas. He also held positions at Wasserstein Perella, First Boston, and Skadden Arps.

George has served on numerous public and private boards and holds A.B., J.D., and M.B.A. degrees from Harvard University.

Alexandra Peterson brings nearly 20 years of experience in investment and operating roles. Among her work, she co-founded a leading ESG advisory, analytics and reporting firm that worked alongside some of the largest alternative fund managers, family offices and Fortune 100s. Alexandra has been listed on Forbes' 30 under 30 and the WSJ’s Women of Note.

Today, Alexandra is a partner at Kittyhawk, an investment firm focused on leading edge seed to late-stage pre-IPO companies. She focuses her personal investing in food and health and serves on numerous advisory boards, including Rockefeller Capital Management.

George Caruolo is a lifelong Rhode Island resident and has been an attorney in Rhode Island and Massachusetts since 1977. He was elected to the Rhode Island House of Representatives in 1980 and became Majority Leader of the chamber in 1993. He retired from elected office in 1998. He has been an advisor and government affairs consultant regionally and nationally.

He has served on various boards, commissions and audit committees including the Rhode Island Coastal Resources Management Council, the Board of Directors of Lifespan, Inc. and he was appointed by Governor Chafee and confirmed by the Rhode Island Senate as Chair of the Rhode Island Board of Regents for Elementary and Secondary Education.

Gaby Toledano is a seasoned board director, advisor, and operating executive with over 30 years of experience in technology, gaming, and digital transformation at Fortune 500 companies such as Tesla, Electronic Arts, Microsoft, and Oracle. She has a deep expertise in talent strategy, executive compensation, CEO coaching, and Diversity, Equity & Inclusion.

Gaby currently serves as Chief Operating Officer at Keystone Strategy, a fast-growing consulting firm based in the US and the UK. She has advised companies like Bumble, Amplitude, and Cerebral, and previously held senior HR roles at Tesla, Electronic Arts, and Siebel Systems. Gaby has served on many public and private boards including GluMobile, Jive Software, Visier, Velo3D, Lilium, Vaxxinity and others.  In addition to Altanine, she currently she serves on the boards of IonQ, a public quantum computing company, as well as Fountain, a private HCM board.

Dr. Pedro Gutiérrez-Castrellón is CEO of Elemental Translational Research SAPI de C.V. and Chief Medical Officer at U.S.-based Cellarion LLC. With over 25 years in translational health research, he has led more than 70 randomized clinical trials across maternal, pediatric, and adult populations.

He founded multiple research organizations in Mexico and held senior roles at the National Pediatric Institute, National Perinatology Institute, IMMS Foundation for Health Research, and GEA General Hospital. Author of over 115 peer-reviewed publications with more than 4,300 citations, he is a recognized leader in microbiota and probiotics research and contributes to international working groups for ESPGHAN and LASPGHAN.

He holds an MD in pediatrics and pediatric intensive care, master’s and doctoral degrees in translational health research and medical science, and an MBA.

Dr. Bruce Forrest is a seasoned biopharmaceutical executive with over 35 years of global leadership in vaccine and therapeutic development. He combines deep R&D expertise with strategic insight in investment banking, recognized for advancing complex programs through alignment across science, manufacturing, and commercialization.

He has extensive experience in Asia-Pacific markets, notably Japan, where he served as Board Member and Head of R&D for Wyeth K.K., leading product approvals for etanercept and gemtuzumab ozogamicin. Earlier, he directed late-phase vaccine development at Wyeth Pharmaceuticals and led major programs including meningococcal C conjugate, rotavirus, pneumococcal, and influenza vaccines. Dr. Forrest holds an M.D. and a PhD, as well as an MBA.

Dr. Richard Evan Greenberg is a retired Master Clinician in Urologic Oncology at the Fox Chase Cancer Center. Trained at New York Hospital and Memorial Sloan-Kettering, he focused on urothelial carcinoma. Over a four-decade career, he was involved in the multidisciplinary management of bladder and upper urinary tract cancers, as well as clinical trials.

He has earned national and international recognition, lecturing in Russia and Belarus for a Department of Defense initiative. Formerly the Chief of Urologic Oncology at Fox Chase, he also held the Carol and Louis Della Penna Chair in Urologic Oncology and was a Professor of Urology at Temple University. He served on the National Comprehensive Cancer Network’s bladder and penile cancer guidelines panels.

Dr. John Macor is President of JEM Pharma Consulting LLC and a member on numerous Scientific Advisory Boards.  He has over 35 years of successful small molecule drug discovery experience with Pfizer, Astra, Bristol-Myers Squibb, Sanofi, and Sionna Therapeutics.  John is co-inventor of four marketed drugs: Nurtec® ODT, Zavzpret®, Filspari®, and Relpax®, in addition to numerous other compounds presently in clinical trials. 

John is co-inventor on over 140 issued US patents and co-author on over 200 peer-reviewed scientific publications.  John has won numerous international awards in medicinal chemistry and is a 2014 inductee into the MEDI Medicinal Chemistry Hall of Fame.  John received a BS degree in chemistry from the University of Notre Dame and a PhD in organic chemistry from Princeton University.

Dr. Jason Mellad is the CEO and Co-Founder of Start Codon, a UK-based accelerator that supports life science and healthcare innovators. With expertise in translating cutting-edge technologies into impactful ventures, he provides seed funding and mentorship through Start Codon’s global network. Previously, he served as CEO of Cambridge Epigenetix and worked in business development at Horizon Discovery.

Dr. Mellad earned a PhD in Medicine from the University of Cambridge as a Marshall Scholar and holds a BSc in Molecular Biology and Chemistry from Tulane University. He resides in Cambridge with his family and is passionate about advancing biotech innovation.

Dr. Richard Pratley is the Samuel E. Crockett Chair in Diabetes Research and Senior Investigator at the AdventHealth Translational Research Institute. He also serves as Medical Director at the AdventHealth Diabetes Institute and is an Adjunct Professor at Johns Hopkins University.

A renowned expert in diabetes, Dr. Pratley has conducted extensive research on diabetes prevention and treatment, with over 400 peer-reviewed publications. Board-certified in internal medicine, he completed his MD at Wayne State University and fellowships at the University of Michigan and Johns Hopkins. He is a frequent lecturer and serves on multiple editorial boards, contributing significantly to diabetes research.

Dr. Franklin Pratt is an internationally recognized public health expert with over 40 years of experience in managing medical crises. He played key roles in the responses to the Oklahoma City bombing, Hurricane Katrina, and the COVID-19 pandemic.

He served as Medical Director for the Los Angeles County Fire Department for 25 years and currently holds a leadership role at the Los Angeles County Department of Public Health. Dr. Pratt is triple board-certified and specializes in emergency medicine, infectious diseases, and public health preparedness. His work has enhanced public health crisis management and improved patient dignity in medical care.